Company intelligence / Profile preview

GreenStar Brands

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

Lobe Sciences (formerly Greenstar Biosciences/GreenStar Brands) is a clinical-stage biotechnology company focused on the development of psychedelic-derived medicines for neurological and mental health conditions. The company specializes in the research and development of stabilized psilocin compounds, such as its lead candidate L-130, to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). Lobe Sciences also explores therapies for rare pediatric diseases and chronic cluster headaches through its synthetic psilocin derivatives. Headquartered in Canada, the company transitioned from a cannabis brand house to a specialized biotech firm to address significant unmet needs in brain health.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on GreenStar Brands.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GreenStar Brands.

Explore the full profile